TGTX is a battleground stock with balanced and rising high long and short interest, with potential for short squeezes after a recent vertical price move.

The company relies on a single drug, BRIUMVI (currently IV only), leaving it exposed to earnings risk and competition from rivals like Roche and Novartis.

Investors are optimistic about upcoming Phase 3 data for a new version of BRIUMVI, which, alongside a stock buyback, supports takeover potential.

TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for B-cell malignancies and autoimmune diseases.

TGTX features a balanced long-to-short interest ratio near 1:1, with both sides increasing exposure. Long interest has risen from 17% to 20%.

Short interest is approximately 18%, pushing the "crowded score" to 77. Given that the short-squeeze score tends to oscillate around this level—and 70 is a key threshold—squeeze risk remains elevated, particularly during market rallies.

The stock has moved sharply higher recently without triggering a short squeeze.

Bear Case: TGTX is highly dependent on BRIUMVI, which is currently approved only for intravenous (IV) administration, not subcutaneous delivery, leaving the company exposed if growth slows or safety issues emerge.

Short sellers expect earnings pressure and competition from large players like Roche and Novartis to limit long-term upside.

Bull Case: Pipeline Catalyst: Investors are focused on Phase 3 data for a subcutaneous formulation of BRIUMVI, which could expand access within the multiple sclerosis market.

Takeover Appeal: Strong commercial traction and a $300 million stock buyback program support the view that the company is a viable acquisition target.

From analysts, roughly 80% of recommendations are positive and only 10% are negative, indicating less dispersion in analyst views than in investor positioning.

Want to know more? Access this data in real time using S3’s BLACK APP & BLACK MAP

The information herein (some of which has been obtained from third party sources without verification) is believed by S3 Partners, LLC (“S3 Partners”) to be reliable and accurate. Neither S3 Partners nor any of its affiliates makes any representation as to the accuracy or completeness of the information herein or accepts liability arising from its use. Prior to making any decisions based on the information herein, you should determine, without reliance upon S3 Partners, the economic risks, and merits, as well as the legal, tax, accounting, and investment consequences, of such decisions.